DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Phase 1

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: BI 765128
Other: Sham comparator

First Posted Date: 2021-06-09

Last Posted Date: 2024-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 46

Registration Number: NCT04919499

Locations: 🇺🇸
Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
🇬🇧
Central Middlesex Hospital, London, United Kingdom
🇺🇸
Bay Area Retina Associates - Walnut Creek, Walnut Creek, California, United States

and more 21 locations

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Phase 3

Completed

Conditions: Stroke

Interventions: Drug: tenecteplase
Drug: alteplase

First Posted Date: 2021-06-07

Last Posted Date: 2024-12-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1489

Registration Number: NCT04915729

Locations: 🇨🇳
Inner Mongolia Baogang Hospital, Baotou, China
🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, China

and more 52 locations

Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database

Completed

Conditions: Diabetes

First Posted Date: 2021-05-26

Last Posted Date: 2024-11-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1233162

Registration Number: NCT04903496

Locations: 🇨🇳
Chengdu Big Data Association, Chengdu, China

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1820237
Drug: Saxenda®
Drug: Paracetamol-ratiopharm®

First Posted Date: 2021-05-26

Last Posted Date: 2022-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT04903509

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Elontril
Drug: BI 1358894

First Posted Date: 2021-05-24

Last Posted Date: 2025-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT04899674

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Drug: Placebo intravenous
Drug: BI 767551 inhalation
Drug: BI 767551 intravenous
Drug: Placebo inhalation

First Posted Date: 2021-05-20

Last Posted Date: 2021-11-08

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT04894474

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Neoplasm Metastasis

Interventions: Drug: zongertinib

First Posted Date: 2021-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 554

Registration Number: NCT04886804

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope-Duarte-56419, Duarte, California, United States
🇺🇸
City of Hope - Seacliff, Huntington Beach, California, United States

and more 83 locations

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

Phase 2

Terminated

Conditions: Chronic Kidney Disease

Interventions: Diagnostic Test: collection of serum/capillary creatinine values

First Posted Date: 2021-05-11

Last Posted Date: 2023-08-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 223

Registration Number: NCT04881448

Locations: 🇺🇸
Med-Care Research, Miami, Florida, United States
🇺🇸
International Research Associates, Miami, Florida, United States
🇺🇸
Tidewater Kidney Specialists, Chesapeake, Virginia, United States

and more 16 locations

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Spesolimab

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT04876391

Locations: 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia
🇨🇦
Dr. S. K. Siddha Medicine Professional Corporation, Newmarket, Ontario, Canada

and more 18 locations

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1291583

First Posted Date: 2021-04-29

Last Posted Date: 2021-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT04866160

Locations: 🇩🇪
Fraunhofer ITEM, Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy